Tonix Pharmaceuticals Holding Corp.
TNXP
$15.71
-$0.15-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.09M | 11.29M | 12.46M | 10.25M | 7.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.09M | 11.29M | 12.46M | 10.25M | 7.77M |
| Cost of Revenue | 7.77M | 8.95M | 9.77M | 6.40M | 4.74M |
| Gross Profit | 2.33M | 2.34M | 2.69M | 3.85M | 3.03M |
| SG&A Expenses | 40.10M | 36.14M | 37.15M | 36.67M | 34.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.84M | 93.88M | 107.64M | 116.08M | 126.15M |
| Operating Income | -77.74M | -82.59M | -95.19M | -105.83M | -118.38M |
| Income Before Tax | -130.04M | -135.25M | -149.01M | -98.59M | -116.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.04 | -135.25 | -149.01 | -98.59 | -116.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.04M | -135.25M | -149.01M | -98.59M | -116.66M |
| EBIT | -77.74M | -82.59M | -95.19M | -105.83M | -118.38M |
| EBITDA | -74.32M | -78.65M | -90.77M | -101.46M | -114.09M |
| EPS Basic | -2.55K | -4.72K | -4.70K | -2.77K | -2.18K |
| Normalized Basic EPS | -693.04 | -686.93 | -672.63 | -369.41 | -- |
| EPS Diluted | -2.55K | -4.72K | -4.70K | -2.77K | -2.18K |
| Normalized Diluted EPS | -693.04 | -686.93 | -672.63 | -369.41 | -- |
| Average Basic Shares Outstanding | 2.95M | 687.40K | 66.20K | 25.30K | -- |
| Average Diluted Shares Outstanding | 2.95M | 699.90K | 78.70K | 37.80K | 12.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |